Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer
Open Access
- 14 September 2026
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (10)
Abstract
Background: The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood. We sought to compare the incidence of neurotoxicity among recipients of polymyxin B or colistin. Methods: This was a single‐center, retrospective cohort study of all patients who received colistin or polymyxin B for the treatment of a serious gram‐negative infection between March 2016 and April 2020. The primary outcome of interest was treatment‐emergent neurotoxicity, defined as new‐onset perioral paresthesia, non‐oral paresthesia, peripheral neuropathy, seizure, diaphragmatic paralysis, or other neurotoxicity. Bivariate analyses were performed using Fisher's exact test and the Wilcoxon rank‐sum test; no multivariable analyses were performed. Results: A total of 82 patients receiving polymyxin B ( n = 39) or colistin ( n = 43) were identified. Neurotoxicity, nearly exclusively paresthesia, was more commonly seen in recipients of polymyxin B (10/39 evaluable patients, 26%) versus colistin (1/42 evaluable patients, 2%; p < 0.01). Neurotoxicity most commonly developed on the first day of therapy and resolved with discontinuation of therapy or prolongation of the infusion duration. Conclusions: Polymyxin B is associated with significantly more neurotoxicity than colistin in unadjusted analyses. This potential risk should be considered when choosing between these two agents.Keywords
This publication has 19 references indexed in Scilit:
- A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) databaseExpert Opinion on Drug Safety, 2024
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)Clinical Microbiology and Infection, 2022
- Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020Clinical Infectious Diseases, 2021
- Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxinsClinical Microbiology and Infection, 2021
- Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)Expert Opinion on Drug Safety, 2021
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and ChemopreventionACS Chemical Neuroscience, 2018
- Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?International Journal of Antimicrobial Agents, 2016
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Neurotoxic and Nephrotoxic Effects of Colistin in Patients with Renal DiseaseNew England Journal of Medicine, 1962